Anti PD-1/anti-CTLA4 therapy either with or without FMD (two cycles) show no benefit against LLC1 tumor growth, whereas FMD in combination with anti-OX40/anti-PD-L1 treatment was the most effective in reducing tumor masses, but this effect was not statistically better than anti-OX40/anti-PD-L1 alone (Fig. 8B). Here, TNFRSF4 is linked to neoplasm.